跳至主要内容
临床试验/NCT06085937
NCT06085937招募中1 期

Feasibility and Safety of Single Dose Ketamine for Acutely Suicidal Patients in the Emergency Department

Lindsay Maguire, MD4 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2024年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
50
试验地点
4
主要终点
Provider and Nursing Attitudes toward use of Ketamine for Suicidal Patients in the ED [Feasibility]

研究概览

简要总结

There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.

详细描述

In this phase one trial, the investigators' objective is to establish the safety and feasibility of the study dose and route of administration, as well as to provide preliminary data on efficacy in reduction of depressive and suicidal symptoms as well as length of stay. Select patients will be given 0.2mg/kg of ketamine IV and observed in the ED for two hours. Vital signs and symptoms will be monitored. Patients will then be transferred to an admitting psychiatric hospital for definitive care as per standard of care. Surveys will be administered at times 0, 2 hours, 24 hours, and 72 hours to assess depressive and suicidal symptoms. ED providers and nursing staff will be asked to complete a short survey assessing ease of use and feasibility for ED administration for this purpose.

Specific aims are as follows:

  1. To determine the safety of ketamine as a single IV dose in the ED for acutely suicidal patients.
  2. To determine the feasibility of ketamine administration in the ED for the acutely suicidal patient.
  3. To determine the impact of ketamine administration on depression and suicidal ideation in the acute phase as measured by the MADRS and C-SSRS.
  4. To determine the impact on hospital length of stay calculated from ED arrival until discharge from admitting psychiatric hospital.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Acutely Suicidality ("yes" answer to any of items 4 or 5 on C-SSRS "Suicidal Ideation" category)
  • Require inpatient stabilization for SI or actions based on clinical observation and interview
  • Are accepted for psychiatric stabilization at the University of Kansas Medical Center's Strawberry Hill campus
  • Have a Glasgow Coma Score (GCS) of 15
  • Age 18-65

排除标准

  • Current or past history of psychosis
  • Current or recent (past 4 weeks) symptoms of mania/hypomania as defined by Young Mania Rating Scale (YRMS) score of 12 or greater
  • History of ketamine use disorder
  • History of liver transplant
  • Pregnancy or breastfeeding
  • Imprisonment or inability to consent
  • Positive urine drug screen or serum alcohol level
  • Hypertension (SBP > 160 or DBP > 100 before administration of ketamine)
  • Hypotension (SBP < 90)
  • Presence of acute medical condition requiring admission to medical service
  • Allergy, intolerance, or previous adverse reaction to ketamine
  • Patient has 8+ lifetime ketamine exposures
  • The treating physician determines that the patient is not a good candidate for the study (e.g. medical condition/procedure, medication that would contradindicate ketamine treatment)

研究组 & 干预措施

Ketamine

Experimental

All patients will receive the experimental drug.

干预措施: Ketamine (Drug)

结局指标

主要结局

Provider and Nursing Attitudes toward use of Ketamine for Suicidal Patients in the ED [Feasibility]

时间窗: 2 hours

A questionnaire will be given to providers and nursing staff to assess \[1\] perceived safety, \[2\] provider comfort, \[3\] perceived efficacy, and \[4\] perceived feasibility for ED use as rated on a Likert scale from 1-5, with 5 relaying best perceived outcomes.

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

时间窗: 2 hours

Safety of use of ketamine for SI in the ED, as assessed by number and severity of reported serious adverse outcomes.

次要结局

  • Change in Suicidal Ideation(72 hours)
  • Hospital Length of Stay(up to 2 weeks)

研究者

发起方
Lindsay Maguire, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Lindsay Maguire, MD

Assistant Professor of Emergency Medicine

University of Kansas Medical Center

研究点 (4)

Loading locations...

相似试验

Feasibility and Safety of Ketamine for Suicidal... | 临床试验